Topical CBD 101 — Practitioner Edition

Full Spectrum contains all naturally occurring cannabinoids, terpenes, and flavonoids from the hemp plant — including trace amounts of THC (≤0.3% by dry weight). This preserves the Entourage Effect, where the full plant matrix produces a broader therapeutic response than any single compound alone. Kannaco's CBD Cooling Cream is Full Spectrum.

Broad Spectrum retains most cannabinoids and terpenes but has THC selectively removed. It offers partial entourage benefits without THC. Kannaco does not currently offer a broad spectrum topical.

Isolate is pure CBD (or CBG) with all other plant compounds removed — 99%+ purity. It is the safest choice for drug-tested patients. Kannaco's Pro Cream and Pro Roll-On use a 1:1 CBD:CBG isolate blend with 0.0% THC confirmed on every COA.

The primary distinction is route of administration and resulting pharmacokinetics. Oral and sublingual CBD enter systemic circulation — they are absorbed through the GI tract or oral mucosa, metabolized hepatically, and distributed throughout the body including the CNS. This produces systemic effects and carries drug interaction risk via the CYP450 pathway.

Topical CBD is applied directly to the skin and acts locally in the dermis and peripheral tissue. It does not produce meaningful blood plasma concentrations, does not cross the blood-brain barrier, and bypasses hepatic metabolism entirely. The result is targeted peripheral receptor engagement without systemic exposure — making it a fundamentally different therapeutic tool.

No. Psychoactivity requires cannabinoids to reach the CNS via systemic circulation. Topical application does not produce systemic absorption at standard application amounts, so cannabinoids cannot reach the brain. There is no risk of psychoactivity, sedation, or cognitive impairment from topical CBD or CBG.

This is true even for full-spectrum products that contain trace THC (≤0.3%). The THC concentration is too low and the absorption route too localized to produce any CNS effect. Patients can apply topical CBD before driving, working, or operating equipment without concern.

Topical CBD presents no known drug interaction risk via the CYP450 pathway. The drug interaction concern with CBD is specific to oral administration, where CBD can inhibit CYP3A4 and CYP2D6 enzymes, affecting the metabolism of medications like blood thinners, antiepileptics, and certain antidepressants.

Because topical CBD bypasses hepatic metabolism entirely, this interaction mechanism does not apply. Patients on complex medication regimens — including anticoagulants, immunosuppressants, and cardiac medications — can generally use topical CBD without concern for pharmacokinetic interactions. As always, clinical judgment and patient-specific context should guide individual recommendations.

For drug-tested patients, the answer depends on the product type. Standard drug tests screen for THC metabolites (THC-COOH). Because topical CBD does not produce systemic absorption, the risk of a positive test from topical application is extremely low even with full-spectrum products.

However, for patients in safety-sensitive roles, competitive athletics, or legal contexts where any THC exposure is unacceptable, recommend Kannaco Pro Cream or Pro Roll-On — both use a 0.0% THC isolate formula confirmed on every third-party COA. This eliminates any theoretical risk entirely and gives patients and practitioners complete confidence.

Cannabigerol (CBG) is a non-psychoactive cannabinoid sometimes called the "mother cannabinoid" because CBGA is the biosynthetic precursor to CBD, THC, and CBC. In peripheral tissue, CBG engages a distinct receptor profile from CBD: it acts as a partial agonist at CB1 and CB2 receptors, an α2-adrenergic agonist, and a 5-HT1A agonist.

Kannaco formulas use CBD and CBG at a 1:1 ratio because their receptor profiles are complementary rather than redundant. CBD targets TRPV1 and inhibits FAAH (raising local anandamide). CBG adds CB1, α2-adrenergic, and 5-HT1A engagement. Together, they activate six distinct peripheral receptor targets — a broader therapeutic coverage than either cannabinoid achieves alone.

Onset varies by individual skin thickness, application area, and product formulation. In general, patients report initial sensory effects (cooling, warming, or tingling from menthol and camphor co-ingredients) within 5–10 minutes. The cannabinoid-mediated effects at peripheral receptors typically develop over 15–45 minutes as the lipophilic cannabinoids penetrate the dermis.

Duration of effect is typically 2–6 hours depending on application amount and activity level. For patients with active or athletic lifestyles, recommend reapplication after exercise or showering. For post-treatment recovery applications in a clinical setting, a single application at the end of a session is generally sufficient.

A practical starting protocol for most patients: apply a dime-to-quarter sized amount to the affected area 2–3 times daily. Massage gently until absorbed. For acute post-treatment recovery, apply immediately following the session and again 4–6 hours later.

There is no established maximum topical dose — the localized nature of topical application means there is no systemic accumulation risk. Patients can increase frequency based on their response. The most common practitioner guidance is: start with twice daily, adjust based on response, and apply consistently for at least 7 days before evaluating efficacy. Consistent daily use produces better results than sporadic application.

Yes. Every Kannaco batch is tested by an ISO-accredited, DEA-registered independent laboratory. Certificates of Analysis (COAs) confirm cannabinoid potency, terpene profile, and absence of pesticides, heavy metals, residual solvents, and microbial contaminants.

COAs are available on the product pages at kannacocbd.com and can be shared directly with patients. As a wholesale account holder, you can also request batch-specific COAs for any product you carry by contacting your account manager. We recommend sharing COAs proactively with patients who ask about testing — it builds trust and differentiates Kannaco from unverified competitors.

The most effective framing for skeptical patients is to lead with what topical CBD is not: it is not psychoactive, it does not enter the bloodstream, it does not interact with their medications, and it does not affect a drug test (especially with isolate formulas). Removing these concerns first makes patients far more receptive.

Then connect it to something familiar: "Your skin has receptors that respond to cannabinoids the same way they respond to other topical compounds you already use — like menthol or arnica. CBD works through those same receptor pathways, locally, right where you apply it." This grounds the mechanism in something concrete and non-threatening. Finish by offering to share the COA so they can see exactly what is in the product. Transparency closes skepticism faster than any claim.